Results 181 to 190 of about 18,962 (231)

Exploring the Use of GLP-1-Based Interventions for Obesity: A Qualitative Analysis of ClinicalTrials.gov Data. [PDF]

Diabetes Metab Syndr Obes
Alourfi NM, Alorfi NM.
europepmc   +1 more source

Glucagon‐Like Peptide‐1 Receptor Agonists in Cocaine Use Disorder: Clinical Observations and Underlying Mechanisms

Fundamental &Clinical Pharmacology, Volume 40, Issue 4, July 2026.
ABSTRACT Background Cocaine use disorder (CUD) remains a major public health concern, characterized by high relapse rates and the absence of approved pharmacological treatments. Glucagon‐like peptide‐1 receptor agonists (GLP‐1RA), widely prescribed for metabolic disorders, modulate mesolimbic reward pathways and have been proposed as potential ...
Céline Eiden, Ghjulia Chautard, Anne Batisse, Aurélie Aquizerate, Amandine Luquiens, Hélène Donnadieu, Jean‐Luc Faillie, Hélène Peyriere   +7 more
wiley   +1 more source

Comparison of Clinical Efficacy and Safety of Tirzepatide, Liraglutide and Semaglutide in Patients with Obesity and Without T2D: A Bayesian Network Meta-Analysis of Randomised Controlled Trials. [PDF]

Adv Ther
Ciudin A, Sapin H, Fan L, Dimitriadis GK, Zimner-Rapuch S, Curteis T, Clark LJ, Rubinstein M, Johansson E.   +8 more
europepmc   +1 more source

GLP‐1 Receptors Are Enriched in the Lymphatic Endothelium and Their Pharmacological Activation With Semaglutide Improves the Pumping Capacity of Lymphatic Vessels

Microcirculation, Volume 33, Issue 5, July 2026.
ABSTRACT Objectives Recent clinical studies have suggested that glucagon‐like peptide‐1 receptor (GLP‐1R) agonists may be effective therapies to treat or reduce the risk of developing secondary lymphedema. In this study, we aimed to (1) determine if GLP‐1Rs are present in the lymphatic vasculature and characterize their expression, and (2) assess the ...
Mary E. Schulz, Victoria L. Akerstrom, Joseph H. Dayan, Jorge A. Castorena‐Gonzalez   +3 more
wiley   +1 more source

GLP-1 agonist liraglutide decreases operant methamphetamine intake in rats under conditions of short- but not extended-access to the drug. [PDF]

Front Pharmacol
Hrickova M, Demirci SF, Amchova P, Ruda-Kucerova J.   +3 more
europepmc   +1 more source

Multidisciplinary Therapy to Target Obesity and Its Complications in Adult Population: A Narrative Review

Obesity Reviews, Volume 27, Issue 7, July 2026.
ABSTRACT Obesity as a chronic and multifactorial disease requires a multidisciplinary team acting together in a holistic multitarget intervention. Multidisciplinary therapy targeting obesity and its complications includes physical exercise, nutritional, and behavior counseling.
Ana Raimunda Dâmaso, Flávia Campos Corgosinho, Deborah Cristina Landi Masquio, Nayra Figueiredo, Fabiana Kattah, Cintia Cercato, Lian Tock, Raquel Munhoz da Silveira Campos   +7 more
wiley   +1 more source

Indications, efficacy, and safety of glucagon-like peptide-1 receptor agonists in respiratory diseases: A systematic review. [PDF]

J Family Med Prim Care
Esmaeel MN, Esmaeel NN, Alhouli RM, Alghareeb NM, Bucheery RA, Booresli YW, Alasoosi RA, Alasoosi BA, Alrashidi AJ, Alawainati MA.   +9 more
europepmc   +1 more source

Efficacy of Weight‐Lowering Agents on Fat Distribution: A Systematic Review and Network Meta‐Analysis of Randomized Controlled Trials

Obesity Reviews, Volume 27, Issue 7, July 2026.
ABSTRACT Background Pharmacotherapy offers a potential solution for individuals with overweight and obesity to decrease their body weight. However, there is limited knowledge of the effects of antiobesity agents on the distribution of body fat. Methods The PubMed, Embase, and Cochrane Library databases were reviewed for randomized controlled trials ...
Xiuqi Qiao, Weihao Wang, Jiaming Cao, Lixin Guo, Qi Pan   +4 more
wiley   +1 more source

Efficacy comparison of dapagliflozin combined with liraglutide versus monotherapy in obese patients with heart failure. [PDF]

Medicine (Baltimore)
Zhou G, Liu A, Hu X, Qi G, Zhang Y.
europepmc   +1 more source